Do Not Administer IVIG for RSV Pneumonia in Infants
Intravenous immunoglobulin (IVIG) should NOT be administered to infants with RSV pneumonia, as there is no evidence of benefit for treatment of established RSV infection.
Evidence Against IVIG for RSV Treatment
The available evidence consistently demonstrates that IVIG has no role in treating active RSV infection:
A 2006 Cochrane systematic review found no statistically significant benefit of IVIG treatment added to supportive care in hospitalized children with laboratory-confirmed RSV infection 1. The review examined mortality, length of hospitalization, length of ventilation, and oxygen dependence—none showed improvement with IVIG.
The most recent 2026 retrospective study (n=157 with propensity score matching) demonstrated that IVIG treatment failed to reduce hospital stay duration (OR=2.566), corticosteroid use duration (OR=4.634), or corticosteroid dosage (OR=4.667) 2. Even after rigorous statistical adjustment through propensity score matching and generalized estimating equations, IVIG showed no benefit. Importantly, subgroup analysis of infants <6 months specifically showed no benefit.
Historical studies from the 1990s examining RSV immune globulin (RSVIG) for treatment of established infection similarly showed no significant reduction in hospitalization duration or intensive care needs 3, 4.
What IVIG IS Indicated For (Not RSV Treatment)
IVIG has specific, evidence-based indications in pediatric infectious disease, but RSV treatment is not among them:
In HIV-Infected Children:
- Hypogammaglobulinemia (IgG <400 mg/dL) to prevent serious bacterial infections 5, 6, 7, 8
- Recurrent serious bacterial infections despite antimicrobial prophylaxis 5, 6
- During RSV season, RSV-IVIG (750 mg/kg, not monoclonal antibody) can substitute for standard IVIG to provide broad protection 5, 6, 8
In Septic Shock:
- NOT routinely recommended for children with septic shock or sepsis-associated organ dysfunction 9
- May have utility in toxic shock syndrome, especially streptococcal etiology 9
- Consider in primary humoral immunodeficiencies or documented low immunoglobulin levels 9
The Correct Approach to RSV in Infants
For Prevention (Not Treatment):
Current 2025 ACIP guidelines recommend prevention through one of three options 10:
- Maternal RSV vaccine (RSVpreF) at 32-36 weeks gestation (September-January)
- Nirsevimab (RSV monoclonal antibody) for infants <8 months
- Clesrovimab (RSV monoclonal antibody) for infants <8 months
These are prophylactic measures, not treatments for active infection.
For Active RSV Pneumonia:
- Supportive care remains the mainstay: oxygen, hydration, respiratory support as needed
- Ribavirin is FDA-approved but systematic reviews show no benefit
- Do not use IVIG—it adds cost, requires IV access, carries risks (renal failure, thrombosis, hemolysis, aseptic meningitis, TRALI) 11, and provides no clinical benefit
Critical Pitfall to Avoid
Do not confuse RSV prophylaxis with RSV treatment. The monoclonal antibodies (palivizumab, nirsevimab, clesrovimab) and maternal vaccination are highly effective at preventing severe RSV disease when given before infection 10, 12, 13. However, once an infant has established RSV pneumonia, neither IVIG nor RSV-specific immunoglobulin provides benefit 2, 1, 14.
The only potential exception would be in immunocompromised patients (such as hematopoietic stem cell transplant recipients) where ribavirin plus IVIG may be considered for RSV lower respiratory tract disease 15, but this is a completely different clinical scenario than an otherwise healthy infant with RSV pneumonia.